PLoS ONE (Feb 2010)

Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.

  • Michèl Schummer,
  • Ann Green,
  • J David Beatty,
  • Beth Y Karlan,
  • Scott Karlan,
  • Jenny Gross,
  • Sean Thornton,
  • Martin McIntosh,
  • Nicole Urban

DOI
https://doi.org/10.1371/journal.pone.0009122
Journal volume & issue
Vol. 5, no. 2
p. e9122

Abstract

Read online

This study was initiated to identify biomarkers with potential value for the early detection of poor-outcome breast cancer. Two sets of well-characterized tissues were utilized: one from breast cancer patients with favorable vs. poor outcome and the other from healthy women undergoing reduction mammaplasty. Over 46 differentially expressed genes were identified from a large list of potential targets by a) mining publicly available expression data (identifying 134 genes for quantitative PCR) and b) utilizing a commercial PCR array. Three genes show elevated expression in cancers with poor outcome and low expression in all other tissues, warranting further investigation as potential blood markers for early detection of cancers with poor outcome. Twelve genes showed lower expression in cancers with poor outcome than in cancers with favorable outcome but no differential expression between aggressive cancers and most healthy controls. These genes are more likely to be useful as prognostic tissue markers than as serum markers for early detection of aggressive disease. As a secondary finding was that, when histologically normal breast tissue was removed from a distant site in a breast with cancer, 7 of 38 specimens displayed a cancer-like expression profile, while the remaining 31 were genetically similar to the reduction mammaplasty control group. This finding suggests that some regions of ipsilateral histologically 'normal' breast tissue are predisposed to becoming malignant and that normal-appearing tissue with malignant signature might warrant treatment to prevent new primary tumors.